EVOQUE Tricuspid Valve Replacement System
Edwards Lifesciences, LLC · Decision date Sep 16, 2026
What did the FDA approve?
The FDA record for P230013/S027, dated 2026-09-16, is a supplement to the EVOQUE Tricuspid Valve Replacement System approval held by Edwards Lifesciences, LLC. It was filed on the Normal 180 Day Track under the labeling-change reason covering indications, instructions, shelf life, or tradename. The stated purpose is to approve modifications to the Instructions for Use, specifically adding internal jugular venous access and revising the sizing table.
Because the identifier links S027 to the original P230013 approval, this is a change to the cleared labeling of an existing device, not a new approval of the whole system. The record gives no detail on the revised sizing criteria, access technique, or any supporting data, and the statement's stated purpose is not independent proof of safety or clinical effectiveness.
FDA approval order statement
Approval for various modifications to the Instructions for Use, including the addition of internal jugular venous access and revision of the sizing table.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 16, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230013/S027
- Regulatory pathway
- PMA supplement
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPW
- Decision code
- APPR
- Decision date
- Sep 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneously Delivered Prostheses and Tricuspid Valves.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230013 · Original PMA
Edwards EVOQUE Tricuspid Valve Replacement System
P230013/S027 received
Application receipt date recorded by FDA.
P230013/S027 · FDA decision
Normal 180 Day Track
P230013/S029 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System
P230013/S033 · Related supplement
EVOQUE Tricuspid Valve Replacement System
P230013/S034 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System (9850EV)
Timeline entries are records held by MedtechLedger for P230013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA approval | Feb 1, 2024 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 19, 2026 | FDA | |
EVOQUE Tricuspid Valve Replacement SystemP230013/S033 | Edwards Lifesciences, LLC | PMA supplement | Oct 21, 2026 | FDA |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P230013/S027
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records